Objectives: In routine clinical practice the selection of a particular anticoagulant for treatment of a specific patient may be based on a variety of different factors. The aim of this study was to explore if there were differences in the characteristics of patients with non-valvular atrial fibrillation (NVAF) who started on dabigatran etexilate (DE) and who in the prior year had no oral anticoagulant treatment (initiators) versus those who had previously been treated with warfarin (switchers). MethOds: Medco claims data were used to characterize 7,055 NVAF patients from the US with a DE prescription between Feb 2011 and Apr 2012. The first prescription in this period defined the index date. The treatment-groups were stratified by initiators and switchers. Characteristics, comedications, and comorbidities in the 12-monthperiod prior to index date were assessed. All illustrated differences were statistically significant (p < 0.05) (1). Results: Switchers (N = 2,585) had a mean age of 74.0 (±9.6) years, whereas initiators (N= 1,903) were younger (mean 70.0 (±9.6) years). A higher proportion of switchers used comedications compared to initiators, e.g. beta blockers (66% vs. 59%), and gastrointestinal drugs (34% vs. 28%). Switchers were more likely to have congestive heart failure, hypertension, cerebrovascular disease, renal disease and bleeding related hospitalizations when compared to the initiators, and also had a higher mean CHA 2 DS 2 -VASc score (4.0 (±1.8) compared to initiators (3.4 (±1.9)). cOnclusiOns: This study shows differences between patients who are initiating DE as first anticoagulant treatment and those who are switched from warfarin to DE revealing that switchers might represent a distinct patient population. Identifying, stratifying or accounting for such differences are necessary in comparisons using real world data. (1) Schoof N et al., Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin. 2013 Dec 27. Objectives: In 2011, various legislative measures were adopted in Slovakia regarding drug policy. The aim of the submitted work is to evaluate links between the introduction of regulations and the consumption of antihypertensive drugs (AH), expenditures and patient co-payments. MethOds: We evaluated data on drugs consumption based on IMS Data. Patient co-payments data were taken from the National Health Information database. When evaluating the average amount of co-payments, we applied a weighted average, which takes into account the level of co-payment and consumption. Results: The consumption of AH (in DOT) increased continually in 2006-2013 (+36%) and the turnover of AH dropped by 4% as a consequence of introducing new regulations. The impact of new regulations was expressed foremost in the consumption of RAS inhibitors, where the decrease in turnover after introduction of clusters in 2012 was 14%. In the evaluated period, the final price of AH was reduced by 35% (from € 8.86 to € 5.78) and the reimbursement was reduced by 52% (from € 7.87 to € 3.76). At the same time, there was an increase in average co-payments by 105% (from € 0.99 to € 2.03). In the evaluated period, the patient co-payment for a fixed AH almost quadrupled (from € 1.05 to € 4.05). The patient paid an average of € 0.93 more for one pack of fixed AH than for a free combination. After the introduction of regulations, the consumption of fixed combinations grew at a slower pace than in the case of monocomponents. cOnclusiOns: The legislative changes in drug policy had a significant impact on the consumption of antihypertensive drugs and on the expense of hypertension treatment. It is necessary to monitor long-term and analyse the impacts of regulations on the prescription of AH and to evaluate factors that can influence the success of hypertension treatment. Objectives: Oral anticoagulants (OACs), used for stroke prevention in atrial fibrillation, include warfarin and the newer drugs (NOACs) dabigatran, rivaroxaban and apixaban. High direct drug costs of the NOACs to the health care payer prompt monitoring of real-world NOAC uptake patterns. This study aimed to identify factors associated with anticoagulation initiation with NOACs versus warfarin. MethOds: Analyses were performed using national pharmacy claims data from a means-tested state medical services scheme. First-time initiators of an oral anticoagulant between January 2009 and December 2013 with ≥ 1 year scheme eligibility and ≥ age 50 were identified. Patients whose claims amounted to < 90 days of oral anticoagulation were excluded. Patient characteristics, and number and type of concomitant medications at the time of first oral anticoagulant were recorded and considered as predictors of NOAC initiation using multivariate logistic models (odds ratios, OR and 95% CIs). Results: 34,944 new initiators of oral anticoagulants were included. In 2009, 7.6% of new initiators received a NOAC; this figure rose to 41.2% in 2013. The following were positively associated with NOAC initiation in multivariate analyses: female gender (OR: 1.14,95% CI 1.07-1.21), age < 80 (OR: 1.11, 95% CI 1.04-1.19) and concomitant receipt of NSAID drugs (OR: 4.04, 95% CI 3.72-4.38). Receipt of multiple concomitant medications was negatively associated with NOAC initiation; patients receiving 15+ drug classes had a 42% decreased odds of NOAC receipt (versus ≤ 5 drug classes) (OR: 0.58, 95% CI 0.51-0.66). Specific concomitant drugs negatively Objectives: Pharmaceutical expenditure accounted for between 11% to 13% of total health expenditure in European countries including Sweden in 2010 whereas this was 20% in Japan for the same year. We expect that big changes in sales pattern will happen as a result of patent expiry. Other changes have been seen when prescribers get negative/positive information on drugs. In this article we study the impact of patent expiry and negative information relating to pharmaceutical policies on pharmaceutical sales patterns of selected drugs in Sweden and Japan. MethOds: we selected angiotensin-converting enzyme inhibitors (ACEs) and Angiotensin Ⅱantagonists (ARBs), since widely used in Sweden and Japan. Seasonal autoregressive integrated moving average (ARIMA) modeling with intervention analysis was used to estimate the change of sales volume. Results: Losartan had a positive change (0.77650, p= 0.0068) in October 2010, Candesartan had a negative change (-0.50760, p= 0.0058) in July 2010. There were no significant differences in the sales volume of Losartan, Telmisartan, except for Candesartan in Japan (0.04868, p= 0.7995, -0.38547, p= 0.0880, and -1.21215, p= 0.001, respectively). In this study, we used a publication informed that Candesartan and Telmisartan had not reduced patients' mortality by a journal July in 2009 as negative information. cOnclusiOns: We found that the sales pattern of selected drugs were changed by negative information and not by the expiry of their patents in Sweden. Whereas in Japan the negative situation for implementing generic substitution like the therapeutic substitution of Trandolapril and the possibility of switching from Candesartan to a combination drug was seen. Further assessment will be needed since factors associated with the changing use of drugs will be infinite. Objectives: From April 2013, the method of calculating the prescription rate of generic drugs in Japan was changed and protected brand name drugs were excluded from the denominator. In the case of Japan, which does not have a reference pricing system, it is thought that this will lead to a change in prescriptions toward protected brand name drugs rather than drug substitution to generic drugs. The objective of this study is to clarify the trends in relation to the prescription of generic drugs, through the use of administrative data on a nationwide level. MethOds: We used survey data from dispensing pharmacies from April 2012 to March 2014. As a comparison, we used the prescription data of 1139 acute care hospitals in which incentive measures for drug substitution to generic drugs had not taken place during the same period. The medical products in question were drugs for diabetes and hypotensive drugs. For data analysis used SQL Server 2008 R2 and R. Results: As the dispensing pharmacy receives additional compensation based on the rate of generic drugs dispensed by that pharmacy in the most recent 3 months, the dispensing rate of generic drugs will have a direct impact on their business. The change in the method of calculating generic drugs has a major impact on the dispensing pharmacies, and in this study we have shown the possibility of dispensing pharmacies shifting more to protected brand name drugs. The dispensing rate of generic drugs by acute care medical facilities has always been low, and thus the impact of the change in calculation of the dispensing ratio is correspondingly low. cOnclusiOns: The results of this study show that when encouraging drug substitution to generic drugs as a policy to reduce drug expenditure, it is necessary to consider measures in relation to the shift to protected brand name drugs.
Objectives: In 2011, various legislative measures were adopted in Slovakia regarding drug policy. The aim of the submitted work is to evaluate links between the introduction of regulations and the consumption of antihypertensive drugs (AH), expenditures and patient co-payments. MethOds: We evaluated data on drugs consumption based on IMS Data. Patient co-payments data were taken from the National Health Information database. When evaluating the average amount of co-payments, we applied a weighted average, which takes into account the level of co-payment and consumption. Results: The consumption of AH (in DOT) increased continually in 2006-2013 (+36%) and the turnover of AH dropped by 4% as a consequence of introducing new regulations. The impact of new regulations was expressed foremost in the consumption of RAS inhibitors, where the decrease in turnover after introduction of clusters in 2012 was 14%. In the evaluated period, the final price of AH was reduced by 35% (from € 8.86 to € 5.78) and the reimbursement was reduced by 52% (from € 7.87 to € 3.76). At the same time, there was an increase in average co-payments by 105% (from € 0.99 to € 2.03). In the evaluated period, the patient co-payment for a fixed AH almost quadrupled (from € 1.05 to € 4.05). The patient paid an average of € 0.93 more for one pack of fixed AH than for a free combination. After the introduction of regulations, the consumption of fixed combinations grew at a slower pace than in the case of monocomponents. cOnclusiOns: The legislative changes in drug policy had a significant impact on the consumption of antihypertensive drugs and on the expense of hypertension treatment. It is necessary to monitor long-term and analyse the impacts of regulations on the prescription of AH and to evaluate factors that can influence the success of hypertension treatment. Objectives: Oral anticoagulants (OACs), used for stroke prevention in atrial fibrillation, include warfarin and the newer drugs (NOACs) dabigatran, rivaroxaban and apixaban. High direct drug costs of the NOACs to the health care payer prompt monitoring of real-world NOAC uptake patterns. This study aimed to identify factors associated with anticoagulation initiation with NOACs versus warfarin. MethOds: Analyses were performed using national pharmacy claims data from a means-tested state medical services scheme. First-time initiators of an oral anticoagulant between January 2009 and December 2013 with ≥ 1 year scheme eligibility and ≥ age 50 were identified. Patients whose claims amounted to < 90 days of oral anticoagulation were excluded. Patient characteristics, and number and type of concomitant medications at the time of first oral anticoagulant were recorded and considered as predictors of NOAC initiation using multivariate logistic models (odds ratios, OR and 95% CIs). Results: 34,944 new initiators of oral anticoagulants were included. In 2009, 7.6% of new initiators received a NOAC; this figure rose to 41.2% in 2013. The following were positively associated with NOAC initiation in multivariate analyses: female gender (OR: 1.14,95% CI 1.07-1.21), age < 80 (OR: 1.11, 95% CI 1.04-1.19) and concomitant receipt of NSAID drugs (OR: 4.04, 95% CI 3.72-4.38). Receipt of multiple concomitant medications was negatively associated with NOAC initiation; patients receiving 15+ drug classes had a 42% decreased odds of NOAC receipt (versus ≤ 5 drug classes) (OR: 0.58, 95% CI 0.51-0.66). Specific concomitant drugs negatively Objectives: Pharmaceutical expenditure accounted for between 11% to 13% of total health expenditure in European countries including Sweden in 2010 whereas this was 20% in Japan for the same year. We expect that big changes in sales pattern will happen as a result of patent expiry. Other changes have been seen when prescribers get negative/positive information on drugs. In this article we study the impact of patent expiry and negative information relating to pharmaceutical policies on pharmaceutical sales patterns of selected drugs in Sweden and Japan. MethOds: we selected angiotensin-converting enzyme inhibitors (ACEs) and Angiotensin Ⅱantagonists (ARBs), since widely used in Sweden and Japan. Seasonal autoregressive integrated moving average (ARIMA) modeling with intervention analysis was used to estimate the change of sales volume. Results: Losartan had a positive change (0.77650, p= 0.0068) in October 2010, Candesartan had a negative change (-0.50760, p= 0.0058) in July 2010. There were no significant differences in the sales volume of Losartan, Telmisartan, except for Candesartan in Japan (0.04868, p= 0.7995, -0.38547, p= 0.0880, and -1.21215, p= 0.001, respectively). In this study, we used a publication informed that Candesartan and Telmisartan had not reduced patients' mortality by a journal July in 2009 as negative information. cOnclusiOns: We found that the sales pattern of selected drugs were changed by negative information and not by the expiry of their patents in Sweden. Whereas in Japan the negative situation for implementing generic substitution like the therapeutic substitution of Trandolapril and the possibility of switching from Candesartan to a combination drug was seen. Further assessment will be needed since factors associated with the changing use of drugs will be infinite. Objectives: From April 2013, the method of calculating the prescription rate of generic drugs in Japan was changed and protected brand name drugs were excluded from the denominator. In the case of Japan, which does not have a reference pricing system, it is thought that this will lead to a change in prescriptions toward protected brand name drugs rather than drug substitution to generic drugs. The objective of this study is to clarify the trends in relation to the prescription of generic drugs, through the use of administrative data on a nationwide level. MethOds: We used survey data from dispensing pharmacies from April 2012 to March 2014. As a comparison, we used the prescription data of 1139 acute care hospitals in which incentive measures for drug substitution to generic drugs had not taken place during the same period. The medical products in question were drugs for diabetes and hypotensive drugs. For data analysis used SQL Server 2008 R2 and R. Results: As the dispensing pharmacy receives additional compensation based on the rate of generic drugs dispensed by that pharmacy in the most recent 3 months, the dispensing rate of generic drugs will have a direct impact on their business. The change in the method of calculating generic drugs has a major impact on the dispensing pharmacies, and in this study we have shown the possibility of dispensing pharmacies shifting more to protected brand name drugs. The dispensing rate of generic drugs by acute care medical facilities has always been low, and thus the impact of the change in calculation of the dispensing ratio is correspondingly low. cOnclusiOns: The results of this study show that when encouraging drug substitution to generic drugs as a policy to reduce drug expenditure, it is necessary to consider measures in relation to the shift to protected brand name drugs.
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Objectives: The objectives of this research are to provide an overview of the recalls of cardiac implant medical devices in the last decade according to the different categories of cardiac implant medical devices and analyze the recall reasons. On the basis of this analysis, this research will provide recommendations on how to build a high quality implant registry. MethOds: A systematic search was performed focusing on regulatory bodies' homepages from a range of middle and high-income countries with sufficient information on cardiac implant recalls and the related reasons. Data was extracted for the years 2004-2014 with the following criteria applied: cardiac implant medical device recalls and reasons for recall, i.e. harm or risk to patients excluding labeling or legal problems. Results: 11 countries have been included in the study: United States, Canada, Australia, New Zealand, PR China, China Hong Kong, UK, Germany, Ireland, Switzerland and Saudi Arabia. 104 recall reports have been analyzed in total. The categories of cardiac implants include the following: Implantable Cardioverter Defibrillator (ICD) 40.4%; pacemaker 14.4%; stent 14.4%; as well as Cardiac Resynchronization Therapy (CRT) 13.5%; leads 9.6% and replacement materials 7.7%. Referring to the recall reasons, 32.7% of the reports related to problems with the device battery; 30.7% of devices were recalled due to incorrect therapy delivery; 15.4% devices had software problems; 15.4% devices had connection problems and 5.8% of devices did not deliver correct output data. cOnclusiOns: Due to the high-risk nature of cardiac implants medical devices and their high complication rates associated with considerable associated mortality, the traceability and transparency of safety hazards information are crucial. By analyzing the recall information including recall reasons and cardiac implants categories, important information is gained that can inform a high quality cardiac implant registry for monitoring the safety of cardiac implant patients.
lor example suggests that a positive National level (NICE) recommendation does not necessarily translate into common local prescribing behavior. Local variation (the fifth hurdle of market access) should be considered by pharmaceutical companies when developing market access strategy. Objectives: Atherosclerotic cardiovascular diseases (CVD) remain the major cause of premature death in Europe. CVD treatment and precribing behavior remains a major challenge for the doctors, payers and regulatory bodies. Key aim of our study was to collect and compare reliable and comparable data on drug utilization for CVD therapy in Slovakia during 8 years (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . MethOds: We utilized review of available costs data sources connected to ATC classification and to cardiovascular diseases (C01-C10). We also looked for Daily Defined Doses (DDD) measurement units. We adopted time frame and data was consequently used for analysis. Costs were used in EUR. Results: Total increase in EUR spent on cardiovascular drugs was more than 60 million EUR (2012 vs It is important for regulatory bodies and payers to continue in taking adequate measures that will ensure rational pharmacotherapy alongside with improving prescribing behavior. Combining different measures, such as electronic prescription monitoring and promoting available guidelines for CVD management, could be an effective way.
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Objectives: According to National Cholesterol Education Program Adult Treatment Panel IV, lipid-lowing agent is required if in patient with atherosclerotic risks. The annual cost of statins consumption was the first five human medications in Taiwan. Therefore, disallowed/deduction of reimbursement from Administration of National Health Insurance (NHI) was relatively higher than other drugs. An "Automatic Laboratory data Checking System" was established in order to enhance rational use of statins and to reduce deduction rate of statins reimbursement. This study aims to analyze the economic outcomes after implemented the system. MethOds: The major cause of deduction was the lipid profile fragmented in the medical record. To ensure rational use of statins based on NHI regulation, an "Automatic Laboratory data Checking System" in computerized physician order entry (CPOE) system was implemented in a teaching hospital on February 2013. When processing a statin prescription through CPOE system, the prescriber should choose the lipid profile linked with laboratory system in our hospital, or filled in lipid profile performed at outside source. The prescription would be blocked if the inspection date and laboratory data were not adherence to the NHI regulation. Results: After system implementation, the deduction of statins reimbursement was significantly decreased. There were three indicators substantially improved in year 2013 than 2012: The average quarterly deduction was 2.16 million NTD reduced, the average quarterly deduction rate was 14% reduced (18.18% versus 3.95%), and the disallowed reimbursement account for 57.11% medication fee decreased to 7.17%. cOnclusiOns: The present study demonstrated that "Automatic Laboratory data Checking System" lessen the economic burden of statins reimbursement based on NHI regulations. The system was associated with rational use of statins and reducing disallowed reimbursement as well. Objectives: This real-world study evaluated the baseline characteristics of patients with non-valvular atrial fibrillation (NVAF) who had switched from warfarin to novel oral anticoagulants (NOACs). MethOds: Retrospective cohort study was conducted using the MarketScan ® plus Earlyview data from 10/1/2009 to 12/31/2013. Adult NVAF patients (ICD-9 code 427.31 or 472.32) with one year of baseline period and a history of continuous warfarin use in the baseline period for at least 3 months immediately before the index date (defined as the first NOAC claim) were included. Patients with evidence of valvular heart disease, thyrotoxicosis, pericarditis, mitral stenosis, VTE, cardiac surgery, and endocarditis during the baseline period were excluded. Categorical variables were reported as percentages and frequencies, and continuous variables as means±SD. Categorical variables were compared using Pearson's chi-squared test while continuous variables were compared using wilcoxon signed-rank test. Objectives: The objective of generic drugs policies can be defined as reduction in health care expenditure without compromising health outcomes. This definition is based on the disinvestment aspect of drug policies. However, the objective of generic drug policies can be also defined from an investment perspective, especially in those countries with volume limits for the use of original patented drugs due to economic constraints: increase in population health gain by improved patient access without need for additional health expenditure. Our objective was to compare benefits of generic drugs policies in Germany vs Hungary. MethOds: We reviewed the grey literature and IMS database to identify pharmaceutical products with (1) patent expiry in recent years, (2) major therapeutic advancement to previous standard therapies, (3) no direct therapeutic alternative at patent expiry, (4) pharmacy distribution and consequently reliable IMS sales records in different countries. Then we compared aggregated annual volume sales in DOT and ex-factory sales for the selected pharmaceuticals in +/-3 years before and after first generic entry. Results: In this analysis we present the case of clopidogrel. In Germany the volume sales of clopidogrel products increased by 1.7% with 3 years after first generic entry, in Hungary the increase was 120.5%. The ex-factory sales were reduced after patent expiry in both countries, by 30.1% in Germany and by 59.5% in Hungary. cOnclusiOns: In Germany off-patent clopidogrel generated significant savings without volume increase. In Hungary generic products significantly improved the accessibility of patients to clopidogrel therapy, in addition to reducing pharmaceutical expenditure. Incremental health gain of off-patent medicines should not be underestimated in those countries, where accessibility of patients to patented medicines in restricted. Objectives: From the total health care costs in Slovak Republic the costs of medicines for treatment of cardiovascular diseases represent about 25%. In the world the proportion is at 8-10%. Accurate data on morbidity from cardiovascular disease in Slovak Republic is not available. National Health Information Center is processing the data on prevalence and incidence of circulatory system diseases, but this includes only those patients who are followed in cardiology in SR. Reportedly, the prevalence of cardiovascular diseases in SR is about 250 000 patients (50.8/ 1000 inhabitants). MethOds: The utilization of medicines in period from 2008 to 2013 for treatment of cardiovascular diseases was analysed quantitatively by inderect descriptiv method of evaluating supply of medicines in quantitative units (number of packages), in the number of DDD and in financial indicators reflecting the full value of consumed package. Data were gained from National Health Center and State Institute of Drug Control. Results: The decline of consumption expressed in number of packages was observed in the group of cardiac therapy and by peripheral vasodilatators. The groups of beta blocking agents, agents acting on the renin-angiotensin system and lipid modifying agents showed increase in consumption. In DDD units the consumption deacreased most significantly in the group of peripheral vasodilatators. Rise in DDD units was observed in the group of beta blocking agents, antihypertesives, beta blocking agents, agents acting on the renin-angiotensin system and lipid modifying agents. Atorvastatin was active agent with highest consumption in DDD. The highest average price per package was calculated by lipid modifying agents. After access of generic drugs to the market in 2008 the consumption in financial units declined while consumption in DDD grew in followed period. cOnclusiOns: By using the same amount of health care expenditures there is the possibility to provide treatment to more patients with cardiovascular disease. 
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